3209 - Beam-Splitting and Pseudo-Proton-ARC Planning Methods for Spatially Fractionated Proton Therapy on a Compact Proton System
Presenter(s)
X. Zhao1, T. R. Mazur1, J. Harms1, N. Knutson1, A. J. Apicelli III1, S. M. Perkins2, and Y. Hao1; 1WashU Medicine, Department of Radiation Oncology, St. Louis, MO, 2WashU Medicine, Department of Radiation Oncology, Saint Louis, MO
Purpose/Objective(s): In a Phase I clinical trial (NCT05831579), spatially fractionated (GRID) proton therapy was delivered using a collimating brass aperture to achieve a customizable spatial dose distribution, escalating dose to small volumes of bulky tumors. However, use of the brass aperture limits flexibility in high dose placement and the beam arrangement. Two non-brass-aperture proton planning approaches, Beam-Splitting (BS), and Pseudo-Proton-Arc (PPArc), are developed and proposed to improve peak-to-valley-dose-ratio (PVDR) and dose conformality compared to proton GRID therapy using a brass aperture.
Materials/Methods: BS and PPArc lattice plans were created for 9 patients with gross tumor volumes (GTVs) from 259-1231 cc. Dose spheres (PTV_6670) were generated within the GTV via scripting, and planned for 66.7 GyRBE dose in 5 fractions, with 4-12 spheres per patient. The whole PTV was prescribed 20 GyRBE. In BS method, a total of 8 fields were placed, with 4 fields utilizing the integrated adaptive aperture fit directly to PTV_6670, and 4 fields covering the remaining PTV_2000. After final optimization, the PTV_6670 subfields and larger PTV_2000 fields with matching gantry/couch angles are merged. In PPArc method, the same optimization objectives were used, with 2-4 arcs consisting of 12 – 16 beams with 15 degrees spacing.
Results: PTV_2000 V20Gy >= 98% was achieved for all plans. PTV_6670 D95% was found to be 95.5±2.1% and 93.3±1.6% in BS and PPArc methods respectively. Average skin Dmax was 33.9±4.0Gy and 32.4±3.9Gy. GTV PVDR, defined as the ratio of the Dmean of PTV_6670 to that of PTV_Avoid, where PTV_Avoid represents the alternating nearest-neighbor spheres to PTV_6670, was 2.7±0.3 and 2.6±0.2, respectively. Furthermore, the OAR constraints in the Phase I photon lattice clinical trial (NCT04133415) were met in all plans.
Conclusion: Dose coverage objectives were met for all 18 proton lattice plans utilizing the integrated adaptive aperture (AA) only. The semi-automated methods developed in this work achieved high-quality lattice plans with increased flexibility in beam arrangement and plan design. BS has fewer beams and better PVDR comparing to PPArc, but higher MUs needed due to the lateral-dose-fall-off control by using the AA. PPArc has less optimization time and skin dose, but is not yet available for clinical use on this compact proton system.
| Treatment Site | Beam-Splitting | Pseudo-Proton-ARC | ||||||
| PVDR | PTV_2000 V100 (%) | PTV_6670 D95 (%) | Skin Dmax (cGy) | PVDR | PTV_2000 V100 (%) | PTV_6670 D95 (%) | Skin Dmax (cGy) | |
| ChestWall | 2.81 | 99.00 | 96.72 | 3614 | 2.58 | 99.33 | 90.28 | 3525 |
| Lung 1 | 3.26 | 98.86 | 99.55 | 3309 | 2.30 | 99.86 | 93.51 | 3447 |
| Lung 2 | 2.59 | 98.59 | 94.41 | 3034 | 2.56 | 99.13 | 93.66 | 2590 |
| Renal | 2.31 | 99.28 | 93.87 | 3671 | 2.59 | 98.91 | 94.41 | 3455 |
| Ribs | 2.26 | 98.48 | 94.78 | 3543 | 2.52 | 98.81 | 94.26 | 3549 |
| Pelvis | 2.80 | 99.01 | 96.13 | 2342 | 2.96 | 98.33 | 94.47 | 2483 |
| Buttock | 2.74 | 98.61 | 96.76 | 3491 | 3.02 | 99.62 | 94.26 | 3267 |
| Paraspinal | 2.74 | 98.45 | 92.94 | 3707 | 2.41 | 98.86 | 91.36 | 3524 |
| Abdomen | 2.71 | 98.11 | 94.44 | 3648 | 2.56 | 99.02 | 93.97 | 3288 |